Economic evaluation of the NET intervention versus guideline dissemination for management of mild head injury in hospital emergency departments

Abstract

Background

Evidence-based guidelines for the management of mild traumatic brain injury (mTBI) in the emergency department (ED) are now widely available, and yet, clinical practice remains inconsistent with the guidelines. The Neurotrauma Evidence Translation (NET) intervention was developed to increase the uptake of guideline recommendations and improve the management of minor head injury in Australian emergency departments (EDs). However, the adoption of this type of intervention typically entails an upfront investment that may or may not be fully offset by improvements in clinical practice, health outcomes and/or reductions in health service utilisation. The present study estimates the cost and cost-effectiveness of the NET intervention, as compared to the passive dissemination of the guideline, to evaluate whether any improvements in clinical practice or health outcomes due to the NET intervention can be obtained at an acceptable cost.

Methods and findings

Study setting: The NET cluster randomised controlled trial [ACTRN12612001286831]. Study sample: Seventeen EDs were randomised to the control condition and 14 to the intervention. One thousand nine hundred forty-three patients were included in the analysis of clinical practice outcomes (NET sample). A total of 343 patients from 14 control and 10 intervention EDs participated in follow-up interviews and were included in the analysis of patient-reported health outcomes (NET-Plus sample). Outcome measures: Appropriate post-traumatic amnesia (PTA) screening in the ED (primary outcome). Secondary clinical practice outcomes: provision of written information on discharge (INFO) and safe discharge (defined as CT scan appropriately provided plus PTA plus INFO). Secondary patient-reported, post-discharge health outcomes: anxiety (Hospital Anxiety and Depression Scale), post-concussive symptoms (Rivermead), and preference-based health-related quality of life (SF6D). Methods: Trial-based economic evaluations from a health sector perspective, with time horizons set to coincide with the final follow-up for the NET sample (2 months post-intervention) and to 1-month post-discharge for the NET-Plus sample. Results: Intervention and control groups were not significantly different in health service utilisation received in the ED/inpatient ward following the initial mTBI presentation (adjusted mean difference $23.86 per patient; 95%CI − $106, $153; p = 0.719) or over the longer follow-up in the NET-plus sample (adjusted mean difference $341.78 per patient; 95%CI − $58, $742; p = 0.094). Savings from lower health service utilisation are therefore unlikely to offset the significantly higher upfront cost of the intervention (mean difference $138.20 per patient; 95%CI $135, $141; p < 0.000). Estimates of the net effect of the intervention on total cost (intervention cost net of health service utilisation) suggest that the intervention entails significantly higher costs than the control condition (adjusted mean difference $169.89 per patient; 95%CI $43, $297, p = 0.009). This effect is larger in absolute magnitude over the longer follow-up in the NET-plus sample (adjusted mean difference $505.06; 95%CI $96, $915; p = 0.016), mostly due to additional health service utilisation. For the primary outcome, the NET intervention is more costly and more effective than passive dissemination; entailing an additional cost of $1246 per additional patient appropriately screened for PTA ($169.89/0.1363; Fieller’s 95%CI $525, $2055). For NET to be considered cost-effective with 95% confidence, decision-makers would need to be willing to trade one quality-adjusted life year (QALY) for 25 additional patients appropriately screened for PTA. While these results reflect our best estimate of cost-effectiveness given the data, it is possible that a NET intervention that has been scaled and streamlined ready for wider roll-out may be more or less cost-effective than the NET intervention as delivered in the trial.

Conclusions

While the NET intervention does improve the management of mTBI in the ED, it also entails a significant increase in cost and—as delivered in the trial—is unlikely to be cost-effective at currently accepted funding thresholds. There may be a scope for a scaled-up and streamlined NET intervention to achieve a better balance between costs and outcomes.

Trial registration

Australian New Zealand Clinical Trials Registry ACTRN12612001286831, date registered 12 December 2012.

Electronic supplementary material

The online version of this article (10.1186/s13012-018-0834-6) contains supplementary material, which is available to authorized users.

Introduction

Evidence-based guidelines for the management of mTBI in the ED are now widely available [1], and yet, clinical practice remains inconsistent with key guideline recommendations (see [2], Table 1). A number of previous studies have estimated the costs and benefits associated with adherence to alternative management strategies for mTBI including selective CT scanning, CT for all patients, skull radiography for all patients, prolonged ED observation, 24-h hospital admission, and no treatment [3–5]. Findings suggest that—at the mean—selective CT scanning is cost-effective in comparison to other strategies and that alternative criteria for selective CT offer ‘broadly similar costs and quality-adjusted life years’ [3] (page 1428). However, each of these previous studies evaluated the cost-effectiveness of perfect adherence to the evaluated management strategies [6]; ignoring the fact that achieving perfect adherence is a difficult and costly undertaking [7–9]. Moreover, each is primarily concerned with adherence to diagnostic management strategies. Evidence-based guidelines for the management of mTBI in the ED include recommendations that extend beyond diagnostic management such as provision of verbal and written patient information upon discharge, and evidence-practice gaps are equally problematic for these recommendations (see [2], Table 1).

Table 1.

Schedule of measures for the economic evaluation

Measures	Data collection	Timing	Source	Level
Clinical practice outcomes
Appropriate PTA screening (PTA)1	Chart audit	Retrospectively for 2 months period post-intervention	ED medical records of eligible patients	Patient
Provision of written patient information (INFO)
Safe discharge (SAFED)2
Clinical patient outcomes and health-related quality of life
Anxiety3	Telephone interview	Ave. 210 days post discharge (SD 38.5 days; IQR 181–239; min = 130, max = 321)	Patient self-report	Patient
Post-concussive symptoms4
HRQoL5
Direct cost of the intervention
Preparation/delivery time and attendance for local training sessions	Questionnaire	On completion of delivery to all EDs	Clinician self-report	ED
Direct cost of all other intervention components	Data abstraction and interview	On completion of delivery to all EDs	Administrative and financial records	ED
Health care utilisation and costs
Medical and surgical services received in the ED/inpatient ward (including CT scan)	Chart audit	Retrospectively on 2 months period post-intervention	ED medical records of eligible patients	Patient
Re-presentation to ED within 1 month of mTBI
Post-discharge mTBI-related service utilisation	Telephone interview	Ave. 210 days post discharge (SD 38.5 days; IQR 181–239; min = 130, max = 321)	Patient self-report	Patient

¹Primary outcome for the economic evaluation

²Defined as PTA, INFO, and CT where CT denotes whether a CT scan was provided in the presence of a risk factor that justifies the scan (age 65 or older; GCS < 15; amnesia; suspected skull fracture; vomiting and coagulopathy) [26] (assessed in the cohort of patients for whom risk criteria were recorded only). CT therefore indicates whether a scan was appropriately provided but not whether a scan was ‘appropriately denied’. CT and SAFED only assessed in the cohort of patients for whom risk criteria were recorded

³Anxiety measured using the relevant questions in the Hospital Anxiety and Depression Scale giving a score between 0 and 21, higher scores indicate higher levels of anxiety, and a score > 7 indicative of clinically significant anxiety

⁴Post-concussion symptoms measured using the 13-item Rivermead scale giving a score between 0 and 52, higher scores indicate greater severity of post-concussion symptoms

⁵12-item short form health survey (SF-12 v2) to derive SF-12-based SF6D index scores using the UK weights from Brazier and Roberts [20]. SF12-based SF6D index scores range between 0.350 (the ‘pits’) and 1.000 (full health)

The Neurotrauma Evidence Translation (NET) intervention was developed to increase the uptake of three key recommendations for the management of adult patients who present to Australian EDs with mTBI [10]. The three recommendations targeted by the NET intervention are as follows:

• Post-traumatic amnesia (PTA) should be prospectively assessed in the emergency department using a validated tool.

• Guideline-developed criteria or clinical decision rules should be used to determine the appropriate use and timing of computed tomography (CT) imaging.

• Verbal and written patient information (consisting of advice, education, and reassurance) should be provided upon discharge from the emergency department (INFO).

The development of the NET intervention was informed by empirical evidence and two theoretical frameworks, selected for their relevance to changing clinician behaviour via implementation interventions in a complex organisational environment [10]. Specifically, factors influencing clinical behaviour change were identified from the Theoretical Domains Framework [11]; organisational factors likely to influence the uptake and implementation of interventions in complex environments such as EDs were identified from the Model of Diffusion of Innovations in Service Organisations [12]. This approach yielded an intervention designed to operate at the level of the clinician and the organisation and to target factors hypothesised to influence uptake of practice recommendations in EDs [13, 14].

The NET Trial [2] aimed to test the effectiveness of the NET intervention for improving management of mTBI in Australian EDs, as compared with the passive dissemination of the relevant guideline [15]. The NET trial estimated the effects of the NET intervention on clinical practice outcomes (NET sample) and on patient-reported health outcomes in a smaller sample of EDs and patients who participated in follow-up interviews (NET-Plus sample). Results from the NET Trial suggest that the NET intervention improves the management of mTBI in the ED; increasing a patient’s chances of being appropriately assessed for PTA and of ‘safe discharge’ (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). However, the improvement in PTA did not clear an a priori specified threshold for clinical significance and the improvement in ‘safe discharge’ mainly reflects the improvement in PTA [2], (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). Detailed results from the main effectiveness analysis of the NET Trial are reported elsewhere (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming).

(Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming) argued that understanding the impact of the intervention on health service utilisation and total cost may be necessary before clear policy recommendations can be drawn from the NET trial. For example, the NET intervention has the potential to reduce some categories of health service utilisation including diagnostic imaging in the ED and unplanned hospital readmissions. The NET intervention also entails an upfront investment that may or may not be fully offset by improvements in clinical practice, health outcomes, and/or reductions in health service utilisation. The economic evaluation described here will explicitly consider this trade-off; first estimating the impact of the intervention on health service utilisation and total cost and then combining treatment effects with respect to cost (incremental cost) and effectiveness (incremental effectiveness) to quantify the incremental cost-effectiveness (incremental cost divided by incremental effectiveness) of the NET intervention.

The complexity of this trade-off has a broader relevance for evidence-based medicine. Closing gaps between evidence and practice is rarely a simple matter [16, 17], and changing clinician behaviour has proven difficult even with tailored, multi-faceted interventions [18, 19]. On the cost side of the equation, attempts to maximise effectiveness by adding facets and complexity, or via the use of tailored rather than ‘off-the-shelf’ interventions, will typically add cost and this may or may not be money well-spent [8, 20]. The present study demonstrates the importance and value of quantifying trade-offs between cost and effectiveness and serves as a reminder that initiatives to increase adherence to guideline recommendations should themselves offer good value for money.

Methods

Study design

The NET study [ACTRN12612001286831] was a cluster randomised controlled trial (CRT) designed to test the effectiveness of the NET intervention for improving management of mTBI in Australian EDs, as compared with the passive dissemination of the relevant guideline [15]. For the present study, trial-based economic evaluations were conducted alongside the NET CRT to quantify the incremental cost-effectiveness of NET intervention in achieving practice change and health outcomes, as compared to the dissemination of the relevant clinical practice guideline. All analyses were conducted from a health sector perspective. The time horizons for the inclusion of relevant costs and consequences coincide with the final scheduled follow-up for the NET sample (2 months post-intervention) and to 1 month post-discharge for the NET-Plus sample. Ethical approval for this study was initially obtained from the Alfred Health Human Research Ethics Committee (approval Number 398/12); local ethics and research governance procedures were subsequently completed for each study site. Please refer to our study protocol [2] for a detailed description of the design of the CRT and methods for the accompanying trial-based economic evaluations.

Study setting and study sample

The economic evaluations alongside the NET study made use of the data at the ED, clinician and patient levels; with recruitment and randomisation procedures for EDs, clinicians, and patients as described in the study protocol [2] and main trial report (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). Briefly, 24-h Australian EDs meeting inclusion criteria whose Directors consented to participate in either NET or NET-Plus were allocated to either the intervention or control group using the method of minimisation. EDs operating for less than 24 h per day, EDs without a CT scanner on site, and EDs in specialised hospitals that do not routinely treat adult patients with TBI (for example, women’s, or children) were excluded. Based on estimates of required sample size (15 EDs per group), to detect a clinically significant 20% change in the primary outcome at the 5% level with approximately 80% power, we aimed to recruit 34 EDs to allow for 10% attrition.

For included EDs, a sample of mTBI patients presenting in the 2 months directly following the local intervention delivery period was selected for inclusion in chart audit using the three-step process described by (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). Patients were eligible for inclusion if they were aged 18 or older, had presented to the ED within 24 h of injury, sustained an acute blunt head trauma, and had a Glasgow Coma Scale score of 14 or 15 at presentation. Patients with penetrating injuries or non-traumatic brain-injury such as stroke were excluded. Patients included in the chart audit and drawn from NET-Plus EDs were subsequently invited to participate in the NET-Plus follow-up of patient-reported health outcomes. At the clinician level, a sample of 50 medical and 50 nursing staff was randomly selected for inclusion in the data collection from a broader list of medical and nursing staff meeting inclusion/exclusion criteria in each participating ED.

Intervention and comparator

EDs randomised to the control group received a copy of the relevant guideline [15] and support in quality assurance for data collection (including reminder stickers and education). EDs randomised to the intervention group received the NET intervention—a complex, multi-faceted intervention that operated at the level of the clinician and the organisation. The NET intervention included the following components:

• (i)Access to the guideline [21],
• (ii)One stakeholder meeting per intervention group ED (1 h duration) between NET clinicians/researchers and local stakeholders (clinicians and management) to secure ‘buy-in’ at the ED level;
• (iii)Identification of local opinion leaders (nursing and medical) via the key-informant method (with ED Directors or Senior Consultants being the key informant for each ED);
• (iv)Delivery of an interactive train-the-trainer workshop to local opinion leaders (1 day duration) led by content experts and NET clinicians and incorporating information provision and skills training;
• (v)Delivery of local workshops (20 min duration) by local opinion leaders to ED staff using provided materials; and
• (vi)Provision of screening tools and information booklets in English and translated into five languages commonly spoken in Australia.

Intervention components were selected to target modifiable barriers and enablers for the implementation of key recommendations regarding the management of mTBI [13, 14]. The design of the NET intervention and its components have been described in detail elsewhere [2, 10, 14, 22]. The delivery of the NET intervention and resources required for each intervention component are described in detail in Additional file 1. Delivery of the comparator or control condition is described in detail in Additional file 2.

Incremental effectiveness

The primary outcome for the main effectiveness analysis, appropriate PTA screening of patients with mTBI (based on chart review), was also specified as the primary outcome for the economic evaluation. Supplementary analyses were also conducted for a number of secondary outcomes. Provision of written information on discharge from the ED (INFO) and ‘safe discharge’ (SAFED, defined as CT scan appropriately provided plus PTA plus INFO) were specified as secondary clinical practice outcomes for economic evaluation in the NET sample. Patient-reported measures of anxiety (Hospital Anxiety and Depression Scale [23, 24]), post-concussive symptoms (13-item Rivermead [25]), and health-related quality of life (SF-12-based SF6D index scores [26–28])1 were specified as secondary patient outcomes for economic evaluation in the NET-Plus sample. Intervention effects with respect to ‘PTA’, ‘INFO’, ‘SAFED’, clinical patient outcomes, and health-related quality of life were estimated using generalised estimating equation (GEE) models as specified for the main effectiveness analysis (see [2], (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming)) in STATA/MP 13.1 for Windows [STATA Corp, 2016]. GEE models appropriately account for correlation of observations clustered within EDs.

Incremental cost

For the NET sample, total cost per patient was calculated as the sum of per patient intervention costs (calculated at the ED level and averaged across patients in each ED) and the per-patient cost of medical and surgical services received in the ED/inpatient ward following their initial mTBI presentation (calculated at the patient level).2 For the NET-Plus sample, the total cost per patient additionally includes the per-patient cost of mTBI-related health service utilisation for a 4-week period, post-discharge from their initial mTBI presentation (calculated at the patient level).

Data sources for each component of total cost are summarised in Table 1 and described in detail in Additional files 1, 2, 3, 4, 5 and 6. Additional files 1 and 2 provide a detailed description of line items and data sources for delivery of the intervention and control conditions. Additional file 3 reproduces health service utilisation items from the chart audit used to estimate resource-use in the ED/inpatient ward. Additional file 4 reproduces health service utilisation items included in phone interviews with NET-Plus participants and used to estimate mTBI-related service utilisation in the post-discharge period. Tables A5-1 and A5-2 in Additional file 5 list unit costs used to convert physical units of resource use to dollar values for delivery of the intervention/control conditions and for health service utilisation, respectively.

Given the characteristic distribution of health costs (truncated at zero and right-skewed), the importance of obtaining readily interpretable marginal effects, and our interest in population-average effects, we modelled intervention effects on total costs using one-part generalised estimating equation (GEE) models with a log link rather than transformed ordinary least squares or two-part models [29]. Specification of the log link for the GEE models permits natural interpretation of marginal effects on cost without retransformation [29]. Correlation structure, standard errors, and controls for confounding variables were as specified for the main effectiveness analysis (see [2], (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming)). Aside from preliminary analyses of costs associated with the delivery of TTT workshops (conducted using Excel 2013), all analyses of total and incremental cost were conducted using STATA/MP 13.1 for Windows [STATA Corp, 2016].

Adjustment for differential timing

All costs were expressed in 2015 AUD by attaching 2015 unit costs where available or inflating actual costs to December quarter 2015 using the all-items Consumer Price Index [30]. For the within-trial analysis presented here, all costs and consequences occurred within a 12-month period, and so, treatment effects were calculated for undiscounted costs and undiscounted benefits.

Incremental cost-effectiveness

Results from the main analysis on the primary outcome were expressed as additional costs (savings) per patient appropriately screened for PTA. For secondary clinical practice outcomes, results were expressed as additional costs (savings) per patient who received patient information upon discharge and per patient safely discharged. For patient-reported health outcomes in the NET-Plus sample, results were expressed as additional costs (savings) per point difference on anxiety questions of Hospital Anxiety and Depression Scale, additional costs (savings) per point difference on the Rivermead Post-Concussive Symptoms (PCS) checklist, and additional costs (savings) per point difference in SF6D utility index scores. Point estimates for incremental cost-effectiveness were calculated as the average treatment effect on total cost per patient divided by the average treatment effect on the relevant outcome.

Uncertainty

Parametric confidence intervals around the incremental cost-effectiveness ratio were derived via the application of Fieller’s Theorem using iprogs.do [31] in STATA/MP 13.1 for Windows [STATA Corp, 2016]. Non-parametric confidence intervals were derived by applying the acceptability method to a distribution of incremental cost-effectiveness ratios generated from bootstrap re-estimation of estimated treatment effects for incremental cost and incremental effectiveness (i.e. bootstrap re-estimation of results from main effectiveness models reported in Tables 3 and 4, with adjustment for minimisation factors and pre-specified confounders as appropriate). Non-parametric confidence intervals and bootstrap re-estimation were implemented using bsceaprogs.do and bmultiv.do [31] in STATA/MP 13.1 or 15.0 for Windows [STATA Corp, 2016; 2017].

Table 3.

Effect of the intervention on clinical practice and patient outcomes

Variable	No. of patients (EDs)		N (%)/mean (SE)		Increment, raw (95%CI)^	Increment, adjusted (95%CI)
	Rx	Control	Rx	Control
Clinical practice outcomes (NET sample)
PTA1	893 (14)	1050 (17)	117 (13.1%)	12 (1.1%)	11.96% (9.8, 14.1)	13.63% (8.3, 19.0)†
INFO	785 (14)	944 (17)	160 (20.4%)	175 (18.5%)	1.84% (− 1.9, 5.6)	3.15% (− 3.0, 9.3)†
SAFED2	402 (14)	413 (17)	14 (3.5%)	0 (0%)	3.49% (1.0, 6.0)	–
Clinical outcomes and quality of life (NET-Plus sample)
Anxiety3	125 (10)	218 (14)	3.43 (0.32)	4.27 (0.27)	− 0.83 (− 1.69, 0.02)	− 0.52 (− 1.34, 0.30)††
Rivermead4	125 (10)	218 (14)	4.73 (0.49)	6.68 (0.59)	− 1.96 (3.65, 0.26)	− 1.15 (− 2.77, 0.48)††
HRQoL5	123 (10)	208 (14)	0.805 (0.01)	0.776 (0.01)	0.029 (− 0.00, 0.06)	0.030 (− 0.00, 0.06)‡

^{^}Increment, raw = unconditional difference in absolute risk or average scores due to exposure to the intervention from two sample t test with equal variances

^†Increment, adjusted = difference in absolute risk due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified confounders: age, sex, out_of_hours, rurality, mTBI protocol, ED participation in NET-Plus, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee, family(binomial) link(logit) corr(exchangeable) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the correlation structure is misspecified

^††Increment, adjusted = difference in average scores due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified confounders: age, sex, out_of_hours, rurality, mTBI protocol, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee, family(Gaussian) link(identity) corr(independent) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the correlation structure is misspecified

‡Increment, adjusted = difference in average scores due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified confounders: age, sex, out_of_hours, rurality, mTBI protocol, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee, family(Gaussian) link(log) corr(independent) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the correlation structure is misspecified

¹Primary outcome for the economic evaluation

²Defined as PTA, INFO, and CT where CT denotes whether a CT scan was provided in the presence of a risk factor that justifies the scan (age 65 or older; GCS < 15; amnesia; suspected skull fracture; vomiting and coagulopathy) [26] (assessed in the cohort of patients for whom risk criteria were recorded only). CT therefore indicates whether a scan was appropriately provided but not whether a scan was ‘appropriately denied’. CT and SAFED only assessed in the cohort of patients for whom risk criteria were recorded

³Anxiety measured using the relevant questions in the Hospital Anxiety and Depression Scale giving a score between 0 and 21, higher scores indicate higher levels of anxiety

⁴Post-concussion symptoms measured using the 13-item Rivermead scale giving a score between 0 and 52, higher scores indicate greater severity of post-concussion symptoms

⁵SF-12v2-based SF6D index scores calculated using weights from Brazier and Roberts [20]. SF-12v2-based SF6D index scores range between 0.350 (the ‘pits’) and 1.000 (full health)

Table 4.

Effect of the intervention on Rx cost, HSU cost, and total cost (per patient)

Variable	No. of patients (EDs)		Mean (SE)		Incremental cost, raw (95%CI)†	Incremental cost, adjusted (95%CI)‡
	Rx	Control	Rx	Control
NET
Rx Cost
Base-case	893 (14)	1050 (17)	$139.0 (1.6)	$0.8 (0.0)	$138.20 (135,141)	–
No URG	893 (14)	1050 (17)	$139.0 (1.6)	$0.8 (0.0)	$138.20 (135,141)	–
HSU Cost
Base-case	893 (14)	1050 (17)	$825.9 (44)	$777.4 (33)	$48.52 (− 57, 154)	$23.86 (− 106,153)
No URG	893 (14)	1050 (17)	$354.0 (42)	$315.7 (31)	$38.35 (− 62, 139)	-$1.08 (− 125,122)
Total Cost
Base-case	893 (14)	1050 (17)	$964.9 (44)	$778.2 (33)	$186.72 (81, 292)	$169.89 (43, 297)
No URG	893 (14)	1050 (17)	$493.0 (42)	$316.5 (31)	$176.55 (76, 277)	$159.96 (39, 281)
NET-Plus, including post-NET HSU
Rx Cost
Base-case	126 (10)	218 (14)	$143.8 (4.6)	$0.8 (0.0)	$142.96 (136,150)	–
No URG	126 (10)	218 (14)	$143.8 (4.6)	$0.8 (0.0)	$142.96 (136,150)	–
HSU Cost
Base-case	126 (10)	218 (14)	$980.8 (235)	$738.5 (72)	$242.38 (− 156,640)	$341.78 (− 58, 742)
No URG	126 (10)	218 (14)	$526.6 (233)	$276.5 (66)	$250.06 (− 137,638)	$338.54 (− 56, 733)
Total Cost
Base-case	126 (10)	218 (14)	$1124.6 (235)	$739.3 (72)	$385.34 (− 12, 783)	$505.06 (96, 915)
No URG	126 (10)	218 (14)	$670.3 (233)	$277.3 (66)	$393.02 (− 6, 780)	$543.49 (116, 971)

†Incremental cost, raw = unconditional difference in cost per patient due to exposure to the intervention from two sample t test with equal variances

‡Incremental cost, adjusted = difference in cost due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified confounders: age, sex, out_of_hours, rurality, mTBI protocol, ED participation in NET-Plus, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee, family(gamma) link(log) corr(exchangeable) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the correlation structure is misspecified

Cost-effectiveness acceptability curves (CEACs) were used to visualise the uncertainty associated with the decision to replace the comparator with the evaluated intervention. CEACs plot the proportion of draws in the bootstrapped distribution of cost-effectiveness for which the intervention is cost-effective, compared to its comparator, at varying funding thresholds (also known as cost-effectiveness thresholds or reference ICERs). In other words, the CEAC tracks changes in the probability that the evaluated intervention is cost-effective as the funding threshold is increased/decreased. For the present study, CEACs were derived using bsceaprogs.do [31] based on data generated from bootstrap re-estimation of our estimates of incremental cost and incremental effectiveness using bmultiv.do [31] in STATA/MP 13.1 or 15.0 for Windows [STATA Corp, 2016; 2017].

Sensitivity analyses were completed using upper/lower bound estimates of uncertain parameters and varying potentially contentious assumptions. For example, the inclusion of urgency-related group (URG) costs for service use in the ED and costs of mTBI-related treatment in the ED for the base-case analysis carries a risk of double-counting; URG costs were therefore excluded in sensitivity analyses to test robustness to this decision. Along similar lines, the inclusion of diagnosis-related group (DRG) costs for service use during inpatient admissions and costs of mTBI-related treatment during inpatient admissions carries a risk of double-counting. However, the inclusion of DRG costs also carries the risk of an additional possible bias, arising from difficulties in identifying mTBI-related admissions and the potential for misclassification of a small number of high-cost admissions to exert undue influence on results. For this reason, DRG costs were excluded from the base-case analysis but included alongside costs of mTBI-related treatment during inpatient admissions in sensitivity analysis.

Results

Participants

A total of 1943 patients from 17 control and 14 intervention EDs (control: n = 1050; intervention: n = 893) were included in the analysis of clinical practice outcomes (NET sample). A total of 343 patients from 14 control and 10 intervention EDs (control: n = 218; intervention: n = 126) participated in follow-up interviews and were included in the analysis of patient-reported health outcomes (NET-Plus sample). Table 2 summarises ED and patient characteristics at baseline for treatment and control groups in both NET and NET-Plus samples.

Table 2.

ED and patient characteristics

	N (%)/mean (SD)	N (%)/mean (SD)	N (%)/mean (SD)	N (%)/mean (SD)
	NET sample		NET-Plus sample
	Control 1	Intervention 2	Control 3	Intervention 4
ED structural characteristics
Hospital type (private)	1 (6%)	1 (7%)	1 (7%)	1 (10%)
Hospital type (public)	16 (94%)	13 (93%)	13 (93%)	9 (90%)
Trauma unit	3 (18%)	4 (29%)	2 (14%)	3 (30%)
Short stay unit	13 (76%)	10 (71%)	10 (71%)	6 (60%)
Annual presentation rate 2012, mean (SD)	44,710 (22593)	41,255 (16512)	44,592 (25046)	36,852 (16913)
Annual presentation rate 2012, median (IQR)	42,495 (34,313 to 46,690)	41,574 (27,075 to 55,667)	38,816 (32,833 to 52,963)	32,612 (25,646 to 47,189)
Existence of protocol for mTBI	4 (24%)	3 (21%)	3 (21%)	3 (30%)
NET-Plus	14 (82%)	13 (93%)	14 (100%)	10 (100%)
Rurality (regional)	7 (41%)	5 (36%)	6 (43%)	4 (40%)
Patient characteristics
Age	50.9 (23.65)	54.2 (24.93)	53.5 (20.59)	55.2 (21.17)
Sex (% male)	476 (45%)	390 (44%)	105 (48%)	51 (41%)
After hours presentation	748 (71%)	653 (73%)	149 (68%)	90 (72%)
Initial GCS 15	961 (92%)	768 (86%)	213 (98%)	115 (92%)
Initial GCS 14	89 (8%)	125 (14%)	5 (2%)	10 (8%)
Mechanism of injury, incidental fall	492 (47%)	481 (54%)	113 (52%)	65 (52%)
Mechanism of injury, road traffic	58 (6%)	51 (6%)	11 (5%)	10 (8%)
Mechanism of injury, violence/assault	250 (24%)	163 (18%)	36 (17%)	15 (12%)
Mechanism of injury, sport	62 (6%)	55 (6%)	17 (8%)	11 (9%)
Mechanism of injury, others	179 (17%)	137 (15%)	41 (19%)	24 (19%)
Mechanism of injury, unclear/not reported	9 (0.9%)	6 (0.7%)	0 (0.0%)	0 (0.0%)
Presence other injuries (outside head)	508 (48%)	516 (58%)	105 (48%)	63 (50%)
Alcohol/illicit drug involvement	237 (23%)	206 (23%)	28 (13%)	15 (12%)
Pre-existing coagulopathy or anti-coagulant or anti-platelet drugs	175 (17%)	165 (18%)	37 (17%)	17 (14%)
Known previous neurological condition	202 (19%)	191 (21%)	26 (12%)	13 (10%)
Known neurosurgery	14 (1.3%)	18 (2.0%)	2 (0.9%)	3 (2.4%)
Scalp laceration	532 (51%)	464 (52%)	130 (60%)	67 (54%)
Scalp haematoma	400 (38%)	372 (42%)	79 (36%)	42 (34%)
Clinical suspicion of skull fracture	51 (4.9%)	57 (6%)	8 (3.7%)	8 (6%)
Loss of consciousness	186 (18%)	155 (17%)	50 (23%)	18 (14%)
Vomiting	56 (5%)	49 (5%)	12 (6%)	4 (3.2%)
Headache	259 (25%)	231 (26%)	44 (20%)	37 (30%)
Post traumatic seizure	3 (0.3%)	6 (0.7%)	0 (0.0%)	2 (1.6%)
Focal neurological deficit	21 (2.0%)	13 (1.5%)	5 (2.3%)	3 (2.4%)

¹Number of patients = 1050; numbers of clusters = 17

²Number of patients = 893; number of clusters = 14

³Number of patients = 218; number of clusters = 14

⁴Number of patients = 125; number of clusters = 10

Incremental effectiveness

Results regarding the effect of the NET intervention on clinical practice outcomes (based on chart audit for treated patients), proxy measures of clinical practice (based on clinician self-report and behavioural simulation), and clinical outcomes (based on patient self-report) have been reported in detail elsewhere (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). Table 3 provides a brief summary of results from the main effectiveness analysis that underpin the economic evaluations reported here. On the primary outcome for the economic evaluation, appropriate PTA screening (based on chart review), patients treated in intervention EDs were 14% more likely to have been treated in line with guideline recommendations than were patients in control EDs (adjusted absolute risk difference 13.63%; 95%CI 8.3%, 19.0%; p < 0.001). On the secondary clinical practice outcome, provision of written patient information (INFO), intervention and control group patients faced about the same chance of being treated in line with guideline recommendations (adjusted absolute risk difference 3.15%; 95%CI − 3.0%, 9.3%; p = 0.316). For the composite indicator of clinical practice, ‘safe discharge’ (SAFED, defined as CT scan appropriately provided plus PTA plus INFO), patients treated in intervention group EDs were more likely to meet the criteria for ‘safe discharge’ (absolute risk difference 3.49%; 95% CI 1.0%, 6.0%; p = 0.0091); with this result being largely driven by the difference in appropriate PTA.

For clinical patient outcomes (NET-Plus sample), there was no statistically significant difference between intervention and control groups for anxiety (adjusted mean difference − 0.52; 95% CI − 1.34–0.30; p = 0.216) or post-concussion symptoms (adjusted mean difference − 1.15; 95% CI − 2.77–0.48; p = 0.167). Finally, SF6D HRQoL scores were higher in the intervention group than in the control group (adjusted mean difference 0.03; 95% CI − 0.00–0.06, p = 0.053). However, this difference fell just short of the pre-specified 0.05 level of statistical significance and it is not clear that the effect is sufficiently large to be considered clinically significant [32, 33].

Incremental cost

The total cost of delivering the NET intervention to the 14 EDs and 893 patients included in the intervention group was just over $124,000 or $139 per patient. Total costs for each component of the NET intervention are detailed in Additional file 1: Table A1-1. The total cost of delivering the control condition to the 17 EDs and 1050 patients in the control group was just under $850 or less than $1 per patient. The total costs for each component of the control condition are detailed in Additional file 2: Table A2-1. These figures demonstrate the much larger upfront cost of the NET intervention (mean difference $138.20; 95% CI $135, $141; p < 0.000).

The total cost of medical and surgical services received in the ED/inpatient ward following the initial mTBI presentation was estimated at $826 in the intervention group and $777 in the control group (adjusted mean difference $23.86; 95% CI − $106, $153; p = 0.719). When combined with intervention delivery costs, the total cost of the NET intervention in the 2 months post-intervention was $965 as compared to $778 for the control condition (adjusted mean difference $169.89; 95% CI $43, $297; p = 0.009).

Results are qualitatively similar over the longer follow-up in the NET-Plus sample. The NET intervention does not appear to deliver savings in health service utilisation (adjusted mean difference $341.78 per patient; 95%CI − $58, $742; p = 0.094). Savings from lower health service utilisation are therefore unlikely to offset the significantly higher upfront cost of the intervention. Once again, estimates of the net effect of the intervention on total cost (intervention delivery cost net of health service utilisation) suggest that the intervention entails significantly higher costs than the control condition (adjusted mean difference $505.06; 95%CI $96, $915; p = 0.016). Table 4 summarises estimation of group totals and increments for intervention delivery, health service utilisation, and total cost.

Incremental cost-effectiveness

The base-case analysis on the primary outcome suggests that the NET intervention is more costly and more effective than passive dissemination, entailing an additional cost of $1246 per additional patient appropriately screened for PTA ($169.89/0.1363). Confidence intervals around the base-case point estimate suggest that—given a sufficiently high funding threshold for the outcome of interest—we can be at least 95% confident that the NET intervention represents good value in comparison to passive dissemination. Upper confidence limits from parametric and non-parametric 95%CIs are $2055 and $2066 respectively, and so, if the funding threshold sits at around $2000 per patient appropriately screened for PTA, then we can be confident that NET delivers good value.

At lower funding thresholds, this finding is reversed and we can be 95% confident that the NET is not cost-effective when compared against passive dissemination. Lower confidence limits from parametric and non-parametric 95%CIs are $525 and $595 respectively, and so, if the funding threshold sits at around $500 per patient appropriately screened for PTA, then we can be 95% confident that passive dissemination delivers better value than the NET intervention. Table 5 summarises results from the cost-effectiveness analysis, including parametric and non-parametric 95%CIs.

Table 5.

Incremental cost-effectiveness for clinical practice and patient outcomes

Variable	ΔC	ΔE	ΔC / ΔE	Parametric (95%CI)†	Non-parametric (95%CI)‡
Clinical practice outcomes (NET sample)
PTA1	$169.89 (43, 297)	0.1363 (0.083, 0.190)	$1246	($525, $2055)	($595, $2066)
INFO2	$169.89 (43, 297)	0.0315 (− 0.030, 0.093)	$5393	($1672,− $18,125)	($1909, − $22,865)
SAFED3	$169.89 (43, 297)	0.0349 (0.010, 0.060)	$4868	($1882, $11928)	($2093, $11574)
Clinical outcomes and quality of life (NET-Plus sample)
HADS Anxiety4	$505.06 (96, 915)	− 0.52 (− 1.34, 0.30)	$971^	($132, − $1086)	($215, − $1084)
Rivermead PCS5	$505.06 (96, 915)	− 1.15 (− 2.77, 0.48)	$441^	($54, − $1270)	($90, − $1346)
SF6D HRQoL6	$505.06 (96, 915)	0.030 (− 0.00, 0.06)	$16,948	($2015,-$367,759)	($3796,-$314,637)

^†Parametric CIs derived via Fieller’s Theorem using iprogs.do [25] based on treatment effects reported in Tables 3 and 4 and using standard errors and correlations calculated from non-parametric bootstrap re-estimation

^‡Non-parametric CIs derived via acceptability method using bsceaprogs.do [25] based on the data generated from bootstrap re-estimation of our estimates of incremental cost and incremental effectiveness using bmultiv.do [25]

¹Cost per patient appropriately screened for PTA (primary outcome)

²Cost per patient who received written patient information upon discharge (INFO)

³Cost per safe discharge (SAFED) where SAFED defined as CT scan appropriately provided plus PTA plus INFO

⁴Cost per point improvement on anxiety questions of Hospital Anxiety and Depression Scale (HADS), higher scores indicate higher levels of anxiety

⁵Cost per point improvement on the Rivermead post-concussive symptoms scale, higher scores indicate greater severity

⁶Cost per point improvement in SF6D index scores, higher scores indicate higher HRQoL

^{^}Calculated as ΔC/− ΔE to reflect the fact that higher scores indicate greater severity for HADS and Rivermead

Figure 1 gives the cost-effectiveness acceptability curve (CEAC) for the primary outcome. The CEAC (solid blue line) plots the relative frequency, or probability, that the NET intervention is cost-effective, compared to passive dissemination at varying levels of the funding threshold expressed in terms of cost per additional patient appropriately screened for PTA. The green and red horizontal lines intersect the CEAC where the NET intervention is cost-effective for 97.5% and 2.5% of the distribution respectively, at funding thresholds of $2066 and $595 per patient appropriately screened for PTA (corresponding with upper and lower confidence limits estimated via the acceptability method). For intermediate thresholds (between the upper and lower confidence limits), we can no longer be so confident that one or other of the two alternatives represents better value for money. For decision-makers interested in lower levels of confidence, NET is the most cost-effective alternative for over 50% of the distribution if the funding threshold exceeds $1250 per patient appropriately screened for PTA.

Fig. 1.

Cost-effectiveness acceptability curve for the primary outcome (PTA)

For PTA and SAFED, we have pattern 1 findings, with the scatter of cost-effect pairs on the cost-effectiveness plane restricted to the northeast (NE) quadrant indicating that the NET intervention is statistically significantly more costly and more effective than passive dissemination [31]. Figure 2 shows the scatter on the cost-effectiveness plane for PTA, providing a graphical description of pattern 1 findings. For INFO, HADS Anxiety, Rivermead PCS, and SF6D HRQoL, we have pattern 2 findings, with the scatter of cost-effect pairs on the cost-effectiveness plane spanning the NE and northwest (NW) quadrants indicating that the NET intervention carries a statistically significantly greater cost than passive dissemination but with no significant difference on the relevant outcome [31]. For pattern 2 findings, the point estimate appears to sit outside the upper and lower confidence limits reported in Table 5, an artefact arising from discontinuities in cost-effectiveness ratios as we move between quadrants on the cost-effectiveness plane. Figure 3 demonstrates the relative position of the point estimate, the scatter, and 95% confidence limits on the cost-effectiveness plane for cost per point improvement on HADS Anxiety and confirms that the point estimate is bounded by upper and lower confidence limits for pattern 2 findings.

Fig. 2.

Cost-effectiveness plane and cost per additional patient appropriately screened for PTA (primary outcome)

Fig. 3.

Cost-effectiveness plane and cost per point improvement on HADS

For INFO, HADS Anxiety, Rivermead PCS, and SF6D HRQoL, there is no funding threshold at which we can be 95% confident that the NET intervention represents good value compared with passive dissemination. However, given a sufficiently low funding threshold for the outcome of interest, we can be at least 95% confident that the NET intervention represents poor value in comparison to passive dissemination. For HADS, lower confidence limits from parametric and non-parametric 95%CIs are $132 and $215 respectively, and so, if the funding threshold sits at around $100 per point improvement on the HADS, then we can be 95% confident that passive dissemination delivers better value than the NET intervention.

For decision-makers interested in lower levels of confidence, it is still possible to identify a funding threshold for INFO, HADS Anxiety, Rivermead PCS, and SF6D HRQoL at which NET is the most cost-effective alternative for a proportion of the distribution (e.g. for over 50% and 80% of the distribution). NET is the most cost-effective alternative for over 50% of the distribution if the funding threshold exceeds $17,000 per point improvement in SF6D index scores, and for over 80% of the distribution if the funding threshold exceeds $34,000 per point improvement in SF6D index scores. For other outcomes, NET was the most cost-effective alternative with 80% probability if the funding threshold exceeds $13,000 per additional patient provided with written patient information, $4500 per point improvement on HADS, and $1000 per point improvement on the Rivermead. Full results available upon request.

Sensitivity analysis

Table 5 reports results from the cost analysis after excluding URG costs to test sensitivity to double counting where, in the base-case, URG costs for service use in the ED (less average imaging costs) have been included alongside costs of mTBI-related treatment in the ED. Results after excluding URG costs are qualitatively identical to results from the base-case analysis. On the primary outcome, the NET intervention is more costly and more effective than the passive dissemination of the relevant guideline (ΔC/ΔE = $159.96/0.1363 = $1174). Confidence intervals around this point estimate suggest that—provided that the funding threshold is above $1958 per additional patient appropriately screened for PTA—we can be at least 95% confident that the delivery of the NET intervention represents good value in comparison to passive dissemination. If, on the other hand, the funding threshold for the primary outcome is less than $469 per additional patient appropriately screened for PTA, then we can be 95% confident that the NET intervention is less cost-effective than passive dissemination. NET is the most cost-effective alternative for over 50% of the distribution if the funding threshold exceeds $1200 per additional patient appropriately screened for PTA.

While results were insensitive to inclusion/exclusion of URG costs, the same cannot be said for inclusion/exclusion of diagnosis-related group (DRG) costs to capture the cost of inpatient admissions. In the base-case analysis, the total cost of the NET intervention in the 2 months post-intervention was $965 as compared to $778 for the control condition (adjusted mean difference $169.89; 95% CI $43, $297; p = 0.009). Including DRG costs alongside costs of mTBI-related treatment during inpatient admissions had the effect of increasing group averages ($1838 versus $1385) and inflating incremental cost (adjusted mean difference $452.91; 95% CI $150, $756; p = 0.003), with predictable consequences for incremental cost-effectiveness across all primary and secondary outcomes. Full results from the sensitivity analyses are available on request.

Discussion

Results suggest that the NET intervention is more costly and more effective than passive dissemination for improving management of mTBI in the ED and that—given sufficiently high funding thresholds for improvements in PTA and safe-discharge—we can be at least 95% confident that the NET intervention represents good value in comparison to passive dissemination. Direct estimates of funding thresholds for PTA and safe discharge are not available and it was not feasible to derive our own estimates as part of the NET study. Further thought is therefore required in order to translate our findings into recommendations for policy and practice.3

Funding thresholds for more commonly used measures of health gain such as quality-adjusted life years (QALYs) have previously been estimated or proposed for different jurisdictions but vary widely and the level and meaning of these funding thresholds has recently become contested [34, 35].4 For any funding threshold expressed in terms of cost per QALY gained, we can calculate ‘bounds’ on the relationship between PTA and QALYs that would need to hold in order for NET to be considered cost-effective. Moreover, we can conduct this exercise for different levels of the cost per QALY threshold in order to evaluate the sensitivity of our findings to an uncertain threshold. In order for the NET intervention to be considered cost-effective with 95% confidence at a funding threshold of $50,000 per QALY, each additional patient appropriately screened for PTA would need to generate ≥ 0.04 additional QALYs (at least 2 weeks of additional life expectancy in full health).5 For a higher (but still plausible) threshold of $100,000 per QALY, each additional patient appropriately screened for PTA would need to generate ≥ 0.02 additional QALYs (at least 1 week of additional life expectancy in full health). For a lower threshold (closer to recent estimates) of $25,000 per QALY, each additional patient appropriately screened for PTA would need to generate ≥ 0.08 additional QALYs (nearly 4.5 weeks of additional life expectancy in full health). Similar trade-offs can be calculated for other outcomes and at other confidence levels.

To put this in context, recent estimates of the population burden of disease for New Zealand suggest that mTBI imposes a total burden of 3277 years of life lost due to disability [36]. Assuming mTBI accounted for 70% of the 527,400 New Zealanders who had experienced at least one TBI, mTBI imposes an average burden of less than 3 days of life lost due to disability per mTBI patient [36]. The average per patient burden of mTBI is therefore less than the average per patient health gain that would have to be generated in order for us to be 95% confident that the NET intervention is cost-effective.

For SF6D index scores, we can obtain a more direct comparison against funding thresholds expressed in cost per QALY terms. While SF6D index scores were not explicitly combined with duration to calculate QALYs, we can calculate an implicit threshold per point improvement in SF6D index scores under different assumptions regarding the duration over which observed SF6D index scores persist and compare this to funding thresholds of $50,000 and $100,000 per QALY. In order for the NET intervention to be considered cost-effective with 80% confidence, the SF6D index scores observed in the NET-Plus sample would need to persist for more than 8 months if we assume a funding threshold of $50,000 per QALY, for more than 4 months if we assume a funding threshold of $100,000 per QALY, and for more than 16 months if we assume a funding threshold of $25,000 per QALY.6

In interpreting our results, several issues should be borne in mind. First, the NET study and main effectiveness analyses had both strengths and limitations that have been documented elsewhere (Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.: Evaluation of a targeted, theory-informed implementation intervention designed to increase uptake of emergency management recommendations regarding adult patients with mild traumatic brain injury: results of the NET cluster randomised controlled trial, Forthcoming). To the extent that the study design and main effectiveness results underpin the cost-effectiveness analyses reported here, then our findings regarding cost-effectiveness are subject to the strengths and limitations of the NET study and main effectiveness analyses. Key strengths of the NET study with particular relevance to the cost-effectiveness analysis include the use of a systematic process to design a multi-faceted intervention, objective measures of clinical practice, and collection of data to inform a process evaluation. With regards to limitations of the NET study, the difficult task of identifying patients for inclusion in chart audit and then recruiting patients into the NET-Plus sample resulted in missing data on secondary health outcomes and raised the potential for selection bias. Along similar lines, secondary clinical outcomes could only be assessed for a subset of patients, potentially resulting in selection bias. While results from supplementary sensitivity analyses (see Additional file 7) suggest that findings from the economic evaluation reported here are robust to any such selection bias, results for secondary outcomes are for a subset of the full study sample and should be interpreted with caution.

Second, the present study estimates the relative cost-effectiveness of the intervention as implemented and may not reflect the relative cost-effectiveness under a wider roll-out. The NET intervention operates on a train-the-trainer model and relies on participation at the organisation level (to permit access to ED staff), at the ED level (to identify local opinion leaders), at the level of local opinion leaders (to attend TTT workshops and deliver local workshops), and at the clinician level (to attend local workshops). While participation in the context of the trial was not always consistent with maximising the effectiveness of the intervention,7 some level of participation was achieved at the organisation, ED, opinion-leader, and clinician levels in the majority of intervention group EDs. This may not be the case in the broader sample of Australian EDs meeting our inclusion/exclusion criteria, some or all of which may be targeted in a wider roll-out of the NET intervention.

While a lower level of participation in any wider roll-out might be expected to render the NET intervention less cost-effective, it is also possible that a NET intervention that has been scaled and streamlined ready for wider roll-out may be more cost-effective than the NET intervention as delivered in the trial. Of particular note, the TTT workshops accounted for over $70,000 or 56% of the total cost of delivering the NET intervention to the 14 intervention group EDs participating in the NET trial. While scale-up may require delivery of additional TTT workshops and would necessitate attendance by local opinion leaders from a larger number of EDs, there may also be scope to increase the number of local opinion leaders trained per workshop. That is to say, it may be possible to double the number of EDs attending the TTT workshop component of the NET intervention at much less than double the estimated cost of delivery.8 Moreover, there may be scope to reduce travel time and direct travel costs where scale-up requires delivery of additional TTT workshops. For example, TTT workshops could be scheduled at a wider range of locations or over a wider range of dates, allowing local opinion leaders to attend a TTT workshop in their home city rather than interstate. Finally, there may be scope to dramatically reduce the cost of TTT workshops using different modes of delivery such as live webinars and/or distribution of digital recordings, potentially resulting in a better balance between costs and effects.

Third, our estimate of incremental cost excludes differences in health service utilisation that may persist beyond the time horizon for the NET-Plus sample. Extending our analysis out to the longer follow-up in the NET-plus sample entailed a threefold increase in average incremental cost, and it is possible that we would see a further divergence between intervention and control groups over an even longer time horizon. Alternatively, the observed intervention effect with respect to health service utilisation may diminish over time; though it is unlikely that we would see a reversal in the observed trend (i.e. lower rather than higher health service utilisation in the treatment group) that would invalidate the results reported here. Nonetheless, the availability of multiple time-points for patient-reported health service utilisation and patient-reported health outcomes in the NET-Plus sample would have allowed us to provide a more complete exploration of the sensitivity of our findings to changes in time horizon.

Fourth, we observed treatment effects with respect to clinical practice and health outcomes only in the study sample and only during the study period. Cost-effectiveness may have been underestimated if treatment effects with respect to clinical practice and health outcomes were also incident upon patients who were treated in intervention-group EDs during the study period but who were not included in the study sample. Similarly, cost-effectiveness may have been underestimated if improvements in patient management observed during the study period persisted beyond the 2-month window from which eligible patients were selected for chart audit and subsequent follow-up of patient-report health outcomes. It may not be immediately apparent how such a bias could arise. The NET intervention operates at the level of the clinician and the organisation, and so intervention costs are semi-fixed in the sense that the cost of delivering treatment effects to one patient (as a consequence of providing all intervention components to one clinician in one ED) is exactly the same as the cost of delivering treatment effects to the total number of mTBI patients treated by one clinician in one ED (for as long as any behaviour change persists). Cost per patient is therefore a function of the number of patients in receipt of the treatment effect, and it may be possible to spread semi-fixed costs over a much larger number of patients than that included in the study sample. If, for example, improvements in patient management due to the intervention could be maintained for several years into the future (i.e. for the 14 intervention-group EDs), then many more patients would receive the benefits of these improvements without the need for any further investment. In this scenario, cost per patient would fall but treatment effects per patient would remain much the same, resulting in a better balance between costs and effects.

Finally, interpretation of results is complicated by the lack of widely accepted funding thresholds for the primary and secondary outcomes. While patient-reported outcomes in the NET-Plus sample included SF12-based SF6D index scores, we were unable to identify secondary data mapping the time path of HRQoL in mTBI patients and decided a priori of commencement of the study not to calculate QALYs by combining SF6D index scores with duration. For clinical practice outcomes and clinical health outcomes, a direct estimate of the funding threshold may have facilitated the interpretation of cost-effectiveness results. We were not able to identify direct estimates of the threshold in the literature, and it was not feasible to derive our own estimates as part of the NET study. In recognition of such difficulties, we make significant efforts to quantify and illustrate decision uncertainty and to couch results in terms of familiar funding decisions (such as whether or not to fund an intervention at a given cost per QALY). Such efforts allowed us to draw clear policy recommendations from our findings despite the lack of widely accepted funding or cost-effectiveness thresholds for the primary and secondary outcomes.

Conclusion

The substantial upfront cost of the NET intervention was not offset by savings in health service utilisation and the NET intervention would therefore need to deliver significant improvements in clinical practice and/or patient outcomes in order for it to be considered cost-effective. As delivered in the trial, the NET intervention does appear to improve management of mTBI in the ED but funding thresholds for these improvements would need to be set implausibly high in order to justify the additional cost of the intervention. This finding serves as a timely reminder that initiatives to increase adherence to guideline recommendations should themselves offer good value for money.

The NET intervention was designed to maximise effectiveness subject to organisational constraints. Further gains in effectiveness may therefore be difficult to achieve without relaxing these organisational constraints. However, it may be possible to achieve a better balance between costs and outcomes by scaling and streamlining the NET intervention, potentially achieving the same or smaller changes in clinical practice but at a lower cost. This has broader implications for the design of implementation interventions—perhaps suggesting greater consideration should be given to smaller bang for (smaller) buck strategies.

Abbreviations

AUD

Australian dollar

CEAC

Cost-effectiveness acceptability curve

CPG

Clinical practice guideline

CRT

Cluster randomised trial

CT

Computed tomography

ED

Emergency department

GCS

Glasgow Coma Scale

HRQoL

Health-related quality of life

ICC

Intra-cluster correlation

ICERs

Incremental cost-effectiveness ratios

INFO

Provision of written patient information upon discharge

mTBI

Mild traumatic brain injury

NET

Neurotrauma Evidence Translation

PCS

Post-concussive symptoms

PTA

Post-traumatic amnesia

QALY

Quality-adjusted life year

SAFED

Safe discharge

TBI

Traumatic brain injury

Authors’ contributions

DM led the design of the trial-based economic evaluation, conducted the analyses of cost and cost-effectiveness and drafted the manuscript. MB, SEG, JEM, RLG, JLP, MC, and JCK participated in the design of the trial-based economic evaluation and suggested edits and revisions to the manuscript. JEM and ST conducted the primary effectiveness analyses. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval for this study was initially obtained from the Alfred Health Human Research Ethics Committee (approval Number 398/12); local ethics and research governance procedures were subsequently completed for each study site. Consent procedures conformed with recent guidance regarding ethical issues in CRTs as described in the trial protocol [2].

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.